Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment

NCT00105417 | Completed Phase 1

• 2 other identifiers: 05011205-I-0112
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate whether interleukin-7 (IL-7) a drug similar to the natural IL-7 protein produced by the body, is safe to use in people infected with HIV. IL-7 is important in immune system function. In humans, it can extend the life of immune cells called T-cells and increase their function and maturation; in mice, it can speed up immune system recovery following chemotherapy of transplantation; and in monkeys, it can make T-cells increase in numbers. If this study shows that IL-7 is safe, other trials will determine if it can improve the numbers or function of T-cells in HIV-infected people. Patients 18 years of age and older with HIV infection who have been taking anti-HIV medications for at least 12 months, whose CD4 counts are at least 100 cells/microliter, and whose viral load is no more than 50,000 copies/milliliter may be eligible for this study. Candidates are screened with a physical examination, blood and urine tests, including a blood test for HLA type (a genetic test of markers of the immune system), chest x-ray, electrocardiogram, and ultrasound of the spleen. Participants undergo the following tests and procedures during 9 visits, as follows: Pre-entry visit

• Brief physical examination, including examination of lymph nodes and spleen.
• Medical history, including questions about current and past medications.
• Urine pregnancy test for women who are able to become pregnant.
• Blood draw for viral load, immune responses, and other routine safety tests. Entry visit
• Complete physical examination, including examination of lymph nodes and spleen.
• Routine urine test and urine pregnancy test for women who are able to become pregnant.
• Blood draw for viral load, immune responses, and other routine safety tests.
• IL-7 dosing. Participants are randomly assigned to receive one of five doses of IL-7 (3, 10, 30, 60 or 100 micrograms per kilogram of body weight) or placebo (a salt solution that does not contain IL-7). The dose may be given in one or more injections, with higher doses possibly requiring as many as seven or eight injections. The injections are given subcutaneously (under the skin), usually in the arm or leg. After the injection, patients are monitored closely for 12 hours for skin or allergic reactions. Blood is drawn before the injection and again at 0.5, 1, 1.5, 2, 2.5, 4, 8 and 12 hours after the injection to check blood levels of the study medication. Follow-up visits Patients come to the clinic 7 times during follow-up-every day for the first 4 days after the injection, then at 14 days, 4 weeks, and 8 weeks after the injection. At most study visits, patients have the following procedures:
• Brief physical examination, including examination of lymph nodes and spleen.
• Routine urine test and urine pregnancy test for women who are able to become pregnant.
• Blood draw for viral load, immune responses, and other routine safety tests.
• Blood test to measure the amount of study medication in the blood 1, 2, and 3 days after the injection
• Electrocardiogram 1 day after the injection

Conditions

HIV Infections; HIV

Keywords

Immune Reconstitution; Thymus; Cytokines; HIV

Interventions

IL-7 DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-1 infection, as documented by any licensed ELISA test kit, and confirmed by Western blot at any time prior to study entry.
• Current treatment with potent ART, defined as any protease inhibitor (PI)-based or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen consisting of at least three antiretroviral drugs, for at least 12 months prior to study entry and stable (i.e., no change in dose) for at least 3 months prior to study entry.
• Note: Changes in a prior potent ART for purposes of simplification to a two-drug regimen that includes a ritonavir (RTV)-boosted PI and efavirenz will be allowed. RTV-boosted PIs will be considered one antiretroviral drug.
• Screening CD4+ cell count greater than or equal to 100 cells/mm(3) obtained within 3-42 days prior to study entry at any CLIA-certified or equivalent laboratory.
• Screening HIV-1 RNA less than or equal to 50,000 copies/mL obtained within 3-42 days prior to study entry using an ultrasensitive assay at any CLIA-certified or equivalent laboratory.
• Note: If HIV-1 RNA is greater than 400 copies/mL, an ultrasensitive assay is not required at screening.
• Documentation that the pre-entry HIV-1 RNA blood draw was obtained within 2-14 days prior to study entry at any CLIA-certified or equivalent laboratory.
• Documentation that the pre-entry CD4+/CD8+ blood draw was obtained within 2-14 days prior to study entry at any CLIA-certified or equivalent laboratory.
• Laboratory values obtained within 3-42 days prior to study entry:
• Absolute neutrophil count (ANC) greater than or equal to 1500/mm(3).
• Hemoglobin greater than or equal to 10.0 g/dL.
• Platelet count greater than or equal to 100,000/mm(3).
• Creatinine less than or equal to 1.5 x upper limit of normal (ULN).
• AST (SGOT), ALT (SGPT), and alkaline phosphatase less than or equal to 2 x ULN.
• Total bilirubin less than or equal to 2.0 x ULN.

You may not qualify if:

• Any history of AIDS-defining illnesses (Category C) during the 12 months prior to study entry. Category C includes the following conditions:
• Candidiasis of bronchi, trachea, or lungs;
• Candidiasis, esophageal;
• Cervical cancer, invasive;
• Coccidioidomycosis, disseminated, or extrapulmonary;
• Cryptococcosis, extrapulmonary;
• Cryptosporidiosis, chronic intestinal (greater than 1 month's duration);
• Cytomegalovirus disease (other than live, spleen, or nodes);
• Cytomegalovirus retinitis (with loss of vision);
• Encephalopathy, HIV-related;
• Herpes simplex: chronic ulcer(s) (greater than 1 month's duration); or bronchitis, pneumonitis, or esophagitis;
• Histoplasmosis, disseminated, or extrapulmonary;
• Isosporiasis, chronic intestinal (greater than 1 month's duration);
• Kaposi's sarcoma;
• Lymphoma, Burkitt's (or equivalent term);

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (1)

National Institute of Allergy and Infectious Diseases (NIAID)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Komschlies KL, Grzegorzewski KJ, Wiltrout RH. Diverse immunological and hematological effects of interleukin 7: implications for clinical application. J Leukoc Biol. 1995 Dec;58(6):623-33. doi: 10.1002/jlb.58.6.623.

  PMID: 7499959 BACKGROUND

• Benjamin D, Sharma V, Knobloch TJ, Armitage RJ, Dayton MA, Goodwin RG. B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J Immunol. 1994 May 15;152(10):4749-57.

  PMID: 8176200 BACKGROUND

• Pandey A, Ozaki K, Baumann H, Levin SD, Puel A, Farr AG, Ziegler SF, Leonard WJ, Lodish HF. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol. 2000 Jul;1(1):59-64. doi: 10.1038/76923.

  PMID: 10881176 BACKGROUND

MeSH Terms

Conditions

HIV Infections

Interventions

Interleukin-7

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Intervention Hierarchy (Ancestors)

Interleukins; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: March 11, 2005
• First Posted: March 14, 2005
• Study Start: March 1, 2005
• Study Completion: May 1, 2006
• Last Updated: March 4, 2008

Record last verified: 2006-05

Locations

US (1)